Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy

被引：21

作者：

Jacobson, MA ^{[1
]}

Liu, L

Khayam-Bashi, H

Deeks, SG

Hecht, FM

Kahn, J

机构：

[1] Univ Calif San Francisco, Dept Med, Posit Hlth Program, San Francisco, CA 94143 USA

[2] San Francisco Gen Hosp, Med Serv, San Francisco, CA 94110 USA

[3] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA USA

[4] San Francisco Gen Hosp, Clin Lab, San Francisco, CA 94110 USA

来源：

AIDS | 2003年 / 17卷 / 06期

关键词：

D O I：

10.1097/00002030-200304110-00019

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We analysed simultaneous CD4, absolute (ALC) and total (TLC) lymphocyte counts of 2057 patients. ALC of 1730 cells/mul or less optimized sensitivity and specificity for predicting CD4 cell counts less than 350 cells/mul. ALC sensitivity/specificity tended to be higher for blacks, patients under 50 years old, and patients with higher plasma HIV-RNA values. TLC values slightly higher than ALC provided virtually identical results. ALC or TLC may be helpful in deciding when to initiate antiretroviral therapy in resource-poor settings.

引用

页码：917 / 919

页数：3

共 10 条

[1]

BHIVA Writing Committee, 2000, HIV Med, V1, P76

[2] TOTAL LYMPHOCYTE COUNT AS A PREDICTOR OF ABSOLUTE CD4+ COUNT AND CD4+ PERCENTAGE IN HIV-INFECTED PERSONS [J].

BLATT, SP ;

LUCEY, CR ;

BUTZIN, CA ;

HENDRIX, CW ;

LUCEY, DR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (05) :622-626

[3] Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel [J].

Carpenter, CCJ ;

Cooper, DA ;

Fischl, MA ;

Gatell, JM ;

Gazzard, BG ;

Hammer, SM ;

Hirsch, MS ;

Jacobsen, DM ;

Katzenstein, DA ;

Montaner, JSG ;

Richman, DD ;

Saag, MS ;

Schechter, M ;

Schooley, RT ;

Vella, S ;

Yeni, PG ;

Volberding, PA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03) :381-390

[4] Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy [J].

Hogg, RS ;

Yip, B ;

Chan, KJ ;

Wood, E ;

Craib, KJP ;

O'Shaughnessy, MV ;

Montaner, JSG .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (20) :2568-2577

[5] When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study [J].

Lepri, AC ;

Phillips, AN ;

Monforte, AD ;

Castelli, F ;

Antinori, A ;

de Luca, A ;

Pezzotti, P ;

Alberici, F ;

Cargnel, A ;

Grima, P ;

Piscopo, R ;

Prestileo, T ;

Scalise, G ;

Vigevani, M ;

Moroni, M .

AIDS, 2001, 15 (08) :983-990

[6]

*PAN CLIN PRACT TR, 2001, GUID US ANT HIV INF

[7] HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load [J].

Phillips, AN ;

Staszewski, S ;

Weber, R ;

Kirk, O ;

Francioli, P ;

Miller, V ;

Vernazza, P ;

Lundgren, JD ;

Ledergerber, B .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (20) :2560-2567

[8] Initiating antiretroviral therapy during HIV infection - Confusion and clarity [J].

Pomerantz, RJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (20) :2597-2599

[9]

Post FA, 1996, QJM-MON J ASSOC PHYS, V89, P505

[10] Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South African patients [J].

van der Ryst, E ;

Kotze, M ;

Joubert, G ;

Steyn, M ;

Pieters, H ;

van der Westhuizen, M ;

van Staden, M ;

Venter, C .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 19 (03) :238-244

← 1 →